一种用于成人异基因造血干细胞移植受者的活体生物治疗产品:一项部分随机、安慰剂对照的Ib期试验
A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial
一项Ib期研究发现,实验性的多菌株口服活体生物治疗产品SER-155在异基因造血干细胞移植受者中的安全性与安慰剂相似,并减少了血流感染,提示其有进一步研究的价值。
Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04686-y
In a phase 1b study that included an open-label and randomized-controlled cohorts of allogeneic hematopoietic cell transplantation recipients, treatment with the investigational, cultivated, multi-strain bacterial oral live biotherapeutic product, SER-155, was found to have a similar safety profile to placebo and resulted in fewer bloodstream infections, indicating further clinical investigation of this therapeutic is warranted.
来源:Nature Medicine · nature.com